Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 22 for “"BH3-mimetics"”.
-
MITOCHONDRIAL MARCH5 UBIQUITIN LIGASE ABROGATES MCL1-DEPENDENT RESISTANCE TO BH3 MIMETICS VIA STABILIZATION OF NOXA
BH3 mimetic compounds induce tumor cell death through targeted inhibition of anti-apoptotic BCL2 proteins. Resistance to one such compound, ABT-737, is due to increased levels of anti-apoptotic MCL1. Using chemical and genetic approaches, we show that resistance to ABT-737 is abrogated by …
-
The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics
… resistance to many therapeutics including the BH3-mimetic agents ABT-199 and ABT-263. The anti-malarial, dihydroartemisinin (DHA) translationally represses MCL-1 and synergizes with BH3-mimetics. To explore how DHA represses MCL-1, a genome-wide CRISPR screen identified that loss of genes in …
-
Investigating the role of BCL-2 family members in chemoresistance in adult and paediatric core-binding factor acute myeloid leukaemia
… such as cytarabine (Ara-C), in AML. BH3 mimetics have shown promise for the treatment of AML, however the use of BH3 mimetics in patients with CBF AML that are resistant to Ara-C remains unclear. Therefore, the broad aim of this project was to determine the role of apoptotic proteins …
-
Characterization of pro- and anti-apoptotic BCL-2 proteins regulating leukemogenesis in juvenile myelomonocytic leukemia (JMML)
… in patients and the JMML xenograft mouse model. BH3-mimetics, small molecules inhibiting pro-survival BCL-2 proteins and thereby inducing apoptosis, were shown to be promising in many cancer entities but have not been used yet in JMML patients. It was the aim of my thesis to study the role of …
-
Quantitative Fast FLIM-FRET (qF3) to Study BCL-2 Family Protein-protein Interactions in Live Cells
… to evade death, so several compounds (called BH3 mimetics) have been developed that inhibit anti-apoptotic proteins, BCL-2, BCL-XL, or MCL-1 to initiate cell death. However, most BCL-2 family proteins have yet to be purified in full-length, and most BH3 mimetics have only been validated using …
-
Functional Effects of a Novel BIM Deletion Polymorphism in Mediating Resistance to Tyrosine Kinase Inhibitors in Cancer
… BIM variants that lacked the apoptosis-inducing BH3 domain. Using cell lines that harbor the deletion, I observed that the deletion was sufficient to confer TKI-resistance in chronic myelogenous leukemia and EGFR-mutated non-small-cell lung cancer. Notably, this resistance can be overcome by …
-
Potentiating oncolytic virus therapy for the treatment of Acute Myeloid Leukaemia
… and examined whether apoptotic modulators (SMAC/ BH3 mimetics) could be used to increase OV efficacy.
-
Beyond Apoptosis: Insight into the Complex Intracellular Networks that Govern Cell Fate
… novel class of small molecule inhibitors called ‘BH3-mimetics’ have emerged as promising anti-cancer therapeutics currently under clinical investigation. Here, we highlight the crosstalk between anti-apoptotic Bcl-2 family member, MCL1, and how it interacts with complex cellular circuits to …
-
Elucidating Non-Canonical Interactions Of Mcl1 With The P53 Family Of Tumor Suppressors
… cells to these apoptotic resistance mechanisms, BH3 mimetics have been developed to selectively target anti-apoptotic proteins in hopes to sensitize a variety of cancers to pro-apoptotic stimuli. This work highlights how the cross talk between the Bcl-2 family of apoptotic regulators impacts the …
-
Mechanisms of AT101 [(-)-Gossypol] Induced Cytotoxicity in Malignant Peripheral Nerve Sheath Tumors
… death pathways and cell survival mechanisms. BH3 mimetics are a novel class of drugs that can induce both apoptosis and autophagy and thus can be effective in MPNST therapy. My studies elucidate the cytotoxic mechanisms of AT101 [(-)-gossypol], a BH3 mimetic, in MPNSTs and further identify key …
-
Molecular targeting of lymphoma through bromodomain inhibition and induction of apoptosis
… able to show that by inhibiting BCL-2 with a BH3-mimetic (ABT- 199) we could resensitise cells with high expression of BCL-2 to BET inhibition. This was seen in murine lymphomas manipulated to upregulate BCL-2, and human lymphomas with high BCL-2 expression both in vitro and in vivo. The …
-
Die Rolle von ausgewählten BH3-only Proteinen in der Lymphozytenentwicklung
… Immunzellen begünstig werden. BH3-Mimetika wie ABT-737 (spezifisch Inhibitoren von Bcl-2, Bcl-XL und Bcl-w), ABT-199 (spezifisch für Bcl-2) oder S63845 (spezifisch für Mcl-1) können unterschiedliche anti-apoptotische Mitglieder der Bcl-2 Familie inhibieren. Für diese Arbeit …
-
Mechanisms of medulloblastoma vulnerability and new targeted therapies
… with clinically used chemotherapeutic drugs and BH3 mimetics, an approach that may boost therapeutic efficacy and reduce treatment-related morbidities.Project 2. Group 3 MB patients have the worst overall survival rates, with MYC amplification/overexpression being the strongest adverse prognostic …
-
Optimising Oncolytic Virotherapy and Immunotherapy for the treatment of Disseminated Colorectal Cancer
… death and stimulate anti-tumour immunity, and BH3-mimetic inhibitors (ABT- 263), which antagonise the BCL-2 family of pro-survival proteins, may enhance CRC patient survival. Harnessing the potential immune and anti- cancer effects of these treatment modalities, alone and in combination, at …
-
Analysis of novel candidate 'BH3-only' proteins
… cell death common to metazoan species. BH3-only proteins can be thought of as ‘linchpins’ in the apoptotic cell death pathway. This is because of their ability to respond to a variety of cell stress signals and to promote apoptosis by interacting with both pro- and anti-apoptotic members …
-
Advances towards the use of radical radiotherapy in malignant pleural mesothelioma
… NU7441 (a DNA-PKcs inhibitor) or A1331852 (a BH3 mimetic) before being exposed to fractionated IR. The immunohistochemical (IHC) expression of DNA-PKcs and Bcl-xL was explored in diagnostic biopsies obtained from MPM patients to investigate clinical validity of the targets. V. IHC expression …
Page 1 of 2